Article
BRAF and EGFR inhibitors synergize to increase cytotoxic effects and decrease stem cell capacities in BRAF(V600E)-mutant colorectal cancer cells.
Acta biochimica et biophysica Sinica - 1 Apr 2018
Wu Zhenhua, Huang Mingzhu, Gong Yiwei, Lin Chen, Guo Weijian
Abstract excerpt
Mutations in the oncogene BRAF(V600E) are found in ~10% of colorectal cancers (CRCs) and are associated with poor prognosis. However, BRAF(V600E) has a limited response to the small-molecule drug, vemurafenib, a BRAF inhibitor, and BRAF inhibition is thought to cause a feedback activation of EGFR signaling that supports continued proliferation. In this study, we explored the effect of combined use of dabrafenib,...
Topics
Join the communities discussing this publication.